Pipeline Advancements

The firm’s pipeline continues to move forward with two Phase 3 trials of barzolvolimab, whose topline data are expected later this year. A Biologics License Application (BLA) submission is planned for 2027. The company’s lead investigational candidate has shown promising Phase 2 results and is expanding into indications such as chronic spontaneous urticaria and prurigo nodularis.